Angioedema following Dipeptidyl Peptidase IV (DPP IV) Inhibitors and Angiotensin Converting Enzyme (ACE) Inhibitors Use: A Descriptive Analysis

Basic Details
Date Posted
Friday, March 26, 2021
Medical Product
angiotensin-converting enzyme (ACE) inhibitor
dipeptidyl peptidase-IV (DPP-IV) inhibitor
Health Outcome(s)

This report examined angioedema among new users of dipeptidyl peptidase IV (DPP IV) inhibitors and/or angiotensin converting enzyme (ACE) inhibitors in the Mini-Sentinel Distributed Database (MSDD). This analysis includes two reports:

  • Report 1: We examined angioedema among individuals with incident exposure to either DPP IV inhibitors or ACE inhibitors.
  • Report 2: We examined angioedema among individuals with concomitant exposures to both DPP IV inhibitors and ACE inhibitors.

The study period includes data from October 16, 2006 to December 31, 2012. We distributed this request to 18 Data Partners on December 20, 2013.

Additional Details
FDA Center
Time Period
October 16, 2006 - December 31, 2012
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
Individuals 20 years of age and older
Data Sources
Mini-Sentinel Distributed Database (MSDD)